# Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.

> **NCT05738473** · — · UNKNOWN · sponsor: **Zhujiang Hospital** · enrollment: 492 (estimated)

## Conditions studied

- Microbiome, Human

## Interventions

- **DRUG:** antibiotic

## Key facts

- **NCT ID:** NCT05738473
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-23
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 492 (ESTIMATED)
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738473, "Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05738473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*